Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
June 06 2023 - 7:00AM
Business Wire
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:
RPTX), a leading clinical-stage precision oncology company, today
announced that data from the ongoing Phase 1/2 TRESR clinical trial
evaluating camonsertib (RP-3500/RG6526, partnered with Roche), a
potent and selective oral small molecule inhibitor of ATR
(Ataxia-Telangiectasia and Rad3-related protein kinase), were
published in Nature Medicine.
The article, entitled “Camonsertib in DNA damage
response-deficient advanced solid tumors: phase 1 trial results”
can be accessed here.
“The results of the TRESR trial demonstrate not only the single
agent activity of camonsertib, a potent and selective ATR
inhibitor, but also define the importance of enhanced precision
medicine approaches, such as the identification of bi-allelic
alterations affecting the target DNA repair genes and other
biomarkers, as well as the use of longitudinal liquid biopsies to
guide its delivery to the right patients,” said Maria Koehler, MD,
PhD, EVP and Chief Medical Officer of Repare. “This study provides
a framework for the testing of novel therapeutic approaches based
on the principles of synthetic lethality and informed by
genome-wide CRISPR screens.”
TRESR (NCT04497116) is a first-in-human, multi-center,
open-label Phase 1/2 dose-escalation and expansion study, designed
to establish the recommended Phase 2 dose and schedule, evaluate
safety and pharmacokinetics and identify preliminary anti-tumor
activity associated with camonsertib, given alone and in
combination with talazoparib or in combination with gemcitabine.
Clinical data were most recently presented at the 2022 and the 2023
American Association for Cancer Research (AACR) Annual Meetings,
demonstrating the promising safety and efficacy profile of
camonsertib, both as a monotherapy and in combination with a poly
(ADP-ribose) polymerase inhibitor.
About Repare Therapeutics’ SNIPRx® Platform
Repare’s SNIPRx® platform is a genome-wide CRISPR-based
screening approach that utilizes proprietary isogenic cell lines to
identify novel and known synthetic lethal gene pairs and the
corresponding patients who are most likely to benefit from the
Company’s therapies based on the genetic profile of their tumors.
Repare’s platform enables the development of precision therapeutics
in patients whose tumors contain one or more genomic alterations
identified by SNIPRx® screening, in order to selectively target
those tumors in patients most likely to achieve clinical benefit
from resulting product candidates.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision
oncology company enabled by its proprietary synthetic lethality
approach to the discovery and development of novel therapeutics.
The Company utilizes its genome-wide, CRISPR-enabled SNIPRx®
platform to systematically discover and develop highly targeted
cancer therapies focused on genomic instability, including DNA
damage repair. The Company’s pipeline includes lunresertib
(RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical
development; camonsertib (RP-3500/RG6526), a potential leading ATR
inhibitor currently in Phase 1/2 clinical development and partnered
with Roche; a preclinical Polθ inhibitor program; as well as
several additional, undisclosed preclinical programs, including
RP-1664. For more information, please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics
Inc.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act of 1995
and securities laws in Canada. All statements in this press release
other than statements of historical facts are “forward-looking
statements. These statements may be identified by words such as
“aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,”
“forecasts,” “goal,” “intends,” “may,” “plans,” “possible,”
“potential,” “seeks,” “will” and variations of these words or
similar expressions that are intended to identify forward-looking
statements, although not all forward-looking statements contain
these words. Forward-looking statements in this press release
include, but are not limited to, statements regarding: the safety,
efficacy and clinical progress of the Company’s clinical programs,
including RP-6306 and camonsertib; the clinical and preclinical
development of the Company’s pipeline and its research and
development programs, including the anticipated timing, anticipated
patient enrollment, trial outcomes or associated costs of its
clinical trials of RP-6306 and camonsertib and ongoing preclinical
studies of the Company's Polθ inhibitor program; the Company’s
continued development of camonsertib in partnership with Roche; the
status of clinical trials (including, without limitation,
expectations regarding the data that is being presented, the
expected timing of data releases and development, as well as
completion of clinical trials) and development timelines for the
Company’s product candidates; selection of a Polθ inhibiting
compound and the Company’s plans and timing with respect to an IND
filing for its Polθ program; the sufficiency of the Company’s cash
resources and its anticipated cash runway into 2026; and the
expected benefits of the Company’s collaborations and partnerships.
These forward-looking statements are based on the Company’s
expectations and assumptions as of the date of this press release.
Each of these forward-looking statements involves risks and
uncertainties that could cause the Company’s clinical development
programs, future results or performance to differ materially from
those expressed or implied by the forward-looking statements. Many
factors may cause differences between current expectations and
actual results, including: the impacts of macroeconomic conditions,
including the COVID-19 pandemic, the conflict in Ukraine, rising
inflation, and uncertain credit and financial markets on the
Company’s business, clinical trials and financial position;
unexpected safety or efficacy data observed during preclinical
studies or clinical trials; clinical trial site activation or
enrollment rates that are lower than expected; changes in expected
or existing competition; changes in the regulatory environment; the
uncertainties and timing of the regulatory approval process; and
unexpected litigation or other disputes. Other factors that may
cause the Company’s actual results to differ from those expressed
or implied in the forward-looking statements in this press release
are identified in the section titled "Risk Factors" in the
Company’s Annual Report on Form 10-K for the year ended December
31, 2022 filed with the Securities and Exchange Commission (“SEC”)
and the Québec Autorité des Marchés Financiers ("AMF") on February
28, 2023, and its other documents subsequently filed with or
furnished to the SEC and AMF. The Company expressly disclaims any
obligation to update any forward-looking statements contained
herein, whether as a result of any new information, future events,
changed circumstances or otherwise, except as otherwise required by
law. For more information, please visit reparerx.com and follow
Repare on Twitter at @RepareRx and on LinkedIn at
https://www.linkedin.com/company/repare-therapeutics/.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230606005502/en/
Repare Contact: Robin Garner Executive Director and Head
of Investor Relations Repare Therapeutics Inc.
investor@reparerx.com
Investors: Matthew DeYoung Argot Partners
repare@argotpartners.com
Media: David Rosen Argot Partners
david.rosen@argotpartners.com 212-600-1902
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From Apr 2024 to May 2024
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From May 2023 to May 2024